NanoViricides Inc. (NNVC)

[Nanotoday]

Is the voucher program awarded to companies to develop their first drug or awarded to companies that have already brought a drug to market (received FDA approval) as an "award" that they can then use on another drug?

This is from the an article on the PRV program:

The PRV is a transferable voucher awarded to a company that receives FDA approval for a new vaccine or drug that prevents or treats a neglected tropical disease, such as malaria, tuberculosis, and intestinal worms. A PRV entitles the bearer to priority review for a future new drug application that would not otherwise qualify for priority review

http://www.bvgh.org/What-We-Do/R-D-Incentives/Priority-Review-Vouchers.aspx

It looks like once a company receives FDA approval for one of the neglected disease medications, it is awarded the PRV for future new drug applications.

Can anyone explain?